Current NDC auxiliary source row compounder:4213

This page is keyed by dataset, FDA.report source record ID, and physical source row number. Empty values are shown rather than omitted.

Complete normalized row#

Record Source: ndc_compounder_zip
Product Ndc Raw: 69194-104
Product Ndc: 69194-104
Product Ndc Digits: 69194104
Product Type Name: HUMAN COMPOUNDED DRUG
Proprietary Name: 104 DILTIAZEM HCL 125MG/125ML
Proprietary Name Suffix: [empty]
Nonproprietary Name: 104 DILTIAZEM HCL 125MG/125ML
Dosage Form Name: INJECTION
Route Name: INTRAVENOUS
Marketing Category Name: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
Labeler Name: Pine Pharmaceuticals LLC
Establishment Name: Pine Pharmaceuticals LLC
Establishment Fei: [empty]
Substance Name: DILTIAZEM HYDROCHLORIDE
Active Ingredients Info: 125 mg/125 mL
History Active Ingredients Raw: DILTIAZEM HYDROCHLORIDE
History Active Ingredients Info Raw: 125 mg/125 mL
History Dosage Raw: INJECTION
Dea Schedule: [empty]
Package Ndc Raw: 69194-104-10
Package Ndc: 69194-104-10
Package Ndc Digits: 6919410410
Package Ndc11: 69194010410
Package Description: 10 BAG in 1 CASE (69194-104-10) > 125 mL in 1 BAG (69194-104-01)
Reporting Period Raw: 2024-2
Reporting Period: 2024-2
Normalization Status: valid
Source Url: https://www.accessdata.fda.gov/cder/compounders_ndc_directory.zip
Source Archive: compounders_ndc_directory.zip
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Last Modified: Fri, 18 Sep 2026 15:17:23 GMT
Source Archive Sha256: 222f6800f79cb1a0fa79431b7226bd6b34899999dbf086af51004a96774ada98
Source Member Sha256: f8d9743e5616579a34d614887e86a53913efa0a63d3138d59d2f87cbb4d0cc17
Source Record Id: compounder:4213
Source Row Number: 4213
Source Row Hash: c99882fbd895c836a45077a1c54826d262f2ee3f2569e5ec3e3c85ba2919c99f
Import Run Id: 20261026T055812Z
Loaded At: 2026-10-26 06:02:33

Exact raw FDA source fields#

{
    "ROUTENAME": "INTRAVENOUS",
    "PRODUCTNDC": "69194-104",
    "DEASCHEDULE": "",
    "LABELERNAME": "Pine Pharmaceuticals LLC",
    "SUBSTANCENAME": "DILTIAZEM HYDROCHLORIDE",
    "DOSAGEFORMNAME": "INJECTION",
    "NDCPACKAGECODE": "69194-104-10",
    "PRODUCTTYPENAME": "HUMAN COMPOUNDED DRUG",
    "PROPRIETARYNAME": "104 DILTIAZEM HCL 125MG/125ML",
    "REPORTINGPERIOD": "2024-2",
    "NONPROPRIETARYNAME": "104 DILTIAZEM HCL 125MG/125ML",
    "PACKAGEDESCRIPTION": "10 BAG in 1 CASE (69194-104-10)  > 125 mL in 1 BAG (69194-104-01) ",
    "ACTIVEINGREDIENTSINFO": "125 mg/125 mL",
    "MARKETINGCATEGORYNAME": "OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)",
    "PROPRIETARYNAMESUFFIX": ""
}

Normalization notes#

[]

Current status projection#

Dataset: compounder
Record Source: ndc_compounder_zip
Source Record Id: compounder:4213
Source Row Number: 4213
Status Scope: package
Lookup Ndc: 69194-104-10
Lookup Ndc Digits: 6919410410
Product Ndc: 69194-104
Product Ndc Digits: 69194104
Package Ndc: 69194-104-10
Package Ndc Digits: 6919410410
Package Ndc11: 69194010410
Product Id: [empty]
Status Code: COMPOUNDER
Status Label: Outsourcing facility compounded drug report
Reporting Period Raw: 2024-2
Reporting Period: 2024-2
Source Table: fda_ndc_aux_compounder
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Row Hash: c99882fbd895c836a45077a1c54826d262f2ee3f2569e5ec3e3c85ba2919c99f
Import Run Id: 20261026T055812Z
Loaded At: 2026-10-26 06:02:33